Some studies have reported a significant correlation between CD133 expression and the clinicopathological characteristics of HCC, including tumor grade, tumor stage, AFP serum level, malignant potential, a higher recurrence rate and a shorter overall survival [31,32,33,34]. The gene discussed is AFP; the disease is hepatocellular carcinoma.